Associated tags: Quality of life, Medicine, Patient, Silicon, Artificial intelligence, Veterinary, SK Telecom, Algorithm, Intelligence, KAIST, Veterinary medicine, Cancer, AI, Stanford University, Research, Hospitals, Prognosis, Oncology, Health, Consumer, Pharmaceutical, General Health
Locations: UNITED STATES, NORTH AMERICA, CALIFORNIA, NEW YORK
Veterinary,
Research,
Technology,
Pets,
Clinical Trials,
Consumer,
Health,
Science,
Oncology,
Artificial Intelligence,
Diagnosis,
AI,
Animal,
Veterinary medicine,
Leukemia,
Artificial intelligence,
Intelligence,
Cornell University,
Patient,
Medicine,
Lymphoma,
Medical device SAVY -- ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced its gold-level sponsorship and participation at the upcoming Symposium on Artificial Intelligence in Veterinary Medicine (SAVY) hosted by the Cornell University College of Veterinary Medicine in Ithaca, New York, from April 19-21, 2024.
Key Points:
- SAVY -- ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced its gold-level sponsorship and participation at the upcoming Symposium on Artificial Intelligence in Veterinary Medicine (SAVY) hosted by the Cornell University College of Veterinary Medicine in Ithaca, New York, from April 19-21, 2024.
- ImpriMed’s timely insights come amid continued adoption of AI’s practical workplace applications in veterinary medicine.
- Our research represents a significant step forward in harnessing technological innovation to advance veterinary medicine,” said Lim.
- “By sharing our findings with like-minded peers, we’re honored to support SAVY in bridging the gap between academic theory and practical application in veterinary AI.”
Retrieved on:
Wednesday, March 20, 2024
Pharmaceutical,
Data Management,
Oncology,
Consumer,
Technology,
Medical Devices,
Artificial Intelligence,
Health Technology,
Clinical Trials,
Veterinary,
Biotechnology,
Health,
Pets,
B-cell lymphoma,
Congress,
Flow cytometry,
Intelligence,
Patient,
Survival,
RBCL,
AI,
Medicine,
Lymphoma,
Trial of the century,
WVCC,
Frontiers Media WVCC -- ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the company’s participation at the upcoming World Veterinary Cancer Congress (WVCC) 2024 in Tokyo, Japan, from March 21-24, 2024.
Key Points:
- WVCC -- ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the company’s participation at the upcoming World Veterinary Cancer Congress (WVCC) 2024 in Tokyo, Japan, from March 21-24, 2024.
- Lim’s presentation will summarize the remarkable results of an ImpriMed study published in Frontiers in Oncology that validate the efficacy of AI-driven drug response predictions in treating canine lymphoma.
- These results, highlighted by Lim’s presentation, demonstrate AI’s powerful application in producing improved clinical outcomes and revolutionizing veterinary oncology.
- "We are honored to advocate for AI’s transformative power by sharing our latest findings at the World Veterinary Cancer Congress," said Lim.
Retrieved on:
Tuesday, December 19, 2023
Veterinary,
Hospitals,
Pets,
Health Technology,
Biotechnology,
General Health,
Pharmaceutical,
Consumer,
Health,
Oncology,
Medicine,
Prognosis,
Research,
SK Telecom,
Stanford University,
AI,
Cancer,
Veterinary medicine,
KAIST,
Silicon,
Patient,
Intelligence,
Algorithm,
Pharmaceutical industry ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the close of a $23 million Series A funding round, led by SBVA.
Key Points:
- ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the close of a $23 million Series A funding round, led by SBVA.
- The funding will enable ImpriMed to expand its revolutionary drug response prediction technology beyond veterinary medicine into human oncology, increase headcount, and broaden its business development and research and development pipeline.
- The only precision medicine company using AI and comprehensive analysis of canine and feline cancer cells to make personalized drug response predictions, ImpriMed is delivering real-world results at scale.
- Its work will arm hospitals with drug treatment response predictions, ensure stronger prognosis evaluations, and more effectively stratify treatment risks.
